ROS1 and non-small cell lung carcinoma: Meanwhile, these patients experienced TEEs relapse within 6 months of their first occurrence, which caused us to focus on anticoagulant treatment in the first 6 months after the first occurrence of TEEs in ROS1-rearranged NSCLC patients.